3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
31
Sarcoma
2
Gynecologic
2
CNS
2
Plasma cell
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Head and Neck Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
8
Nasopharyngeal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Recurrence
2
Osteosarcoma
2
Optic Nerve Glioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasm Metastasis
2
Melanoma
2
Familial ependymoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
Trastuzumab
3
Docetaxel
3
Cisplatin
3
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Capecitabine
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
tipifarnib
1
seribantumab
1
sargramostim
1
pertuzumab
1
lenvatinib
1
entinostat
1
Thalidomide
1
Taxes
1
Specimen Handling
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Immunohistochemistry
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Oxaliplatin
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled